Dasatinib Monohydrate (BMS-354825): Potent ATP-Competitive Multitargeted Tyrosine Kinase Inhibitor for Hematological and Solid Tumor Research

Executive Summary: Dasatinib Monohydrate (BMS-354825) is a multitargeted ATP-competitive kinase inhibitor with nanomolar IC₅₀ values against ABL, SRC, KIT, and PDGFR kinases, demonstrating strong activity in both nonmutated and imatinib-resistant BCR-ABL isoforms (APExBIO). It is FDA-approved for treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), particularly in cases of imatinib failure (Shapira-Netanelov et al., 2025). In vitro and in vivo studies confirm its antiproliferative efficacy across hematological and solid tumor models. Dasatinib Monohydrate enables high-fidelity modeling of kinase-driven disease and resistance in next-generation assembloid systems. Proper formulation, storage at -20°C, and short-term use of DMSO solutions are essential for maintaining compound stability and experimental reproducibility.

Biological Rationale

Tyrosine kinases regulate cell proliferation, survival, and differentiation through phosphorylation-dependent signaling pathways. Dysregulation of ABL, SRC, KIT, and PDGFR kinases is implicated in hematological malignancies and solid tumors (Shapira-Netanelov et al., 2025). The BCR-ABL fusion protein, resulting from the Philadelphia chromosome translocation, drives chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Resistance to first-generation inhibitors, such as imatinib, often arises from point mutations (e.g., M351T), necessitating second-generation inhibitors with broader target spectra and improved potency. Targeting multiple kinases simultaneously can overcome compensatory signaling and resistance mechanisms, supporting the development of multitargeted inhibitors like Dasatinib Monohydrate.

Mechanism of Action of Dasatinib Monohydrate

Dasatinib Monohydrate (BMS-354825) is an ATP-competitive inhibitor that binds to the catalytic domains of ABL, SRC family kinases, KIT, and PDGFR, preventing phosphorylation of downstream substrates. It exhibits an IC₅₀ of 0.55 nM for Src and 3.0 nM for Bcr-Abl kinases in in vitro kinase inhibition assays (APExBIO). Dasatinib inhibits both wild-type and imatinib-resistant BCR-ABL isoforms, including clinically relevant mutants such as M351T. The compound exerts antiproliferative and cytotoxic effects in BCR-ABL–positive leukemia cells and exhibits efficacy in solid tumor models by suppressing SRC-mediated signaling pathways. In vivo, oral Dasatinib administration reduces disease progression and bioluminescent tumor activity in murine models harboring BCR-ABL mutations. These multimodal inhibitory actions make Dasatinib Monohydrate uniquely effective in preclinical and translational oncology research (see Mechanistic and Benchmark Data).

Evidence & Benchmarks

• Dasatinib Monohydrate displays nanomolar potency (IC₅₀ 0.55 nM for Src, 3.0 nM for Bcr-Abl) in biochemical kinase inhibition assays (APExBIO).
• In preclinical CML models, Dasatinib overcomes resistance conferred by BCR-ABL point mutations (including M351T), significantly reducing leukemic burden in vivo (Shapira-Netanelov et al., 2025).
• FDA approval covers chronic, accelerated, and blast phases of CML, as well as Ph+ ALL, particularly after imatinib failure (FDA label).
• Patient-derived gastric cancer assembloid models reveal stromal subpopulations modulate Dasatinib response, underscoring the importance of tumor microenvironment in drug sensitivity (Shapira-Netanelov et al., 2025).
• Dasatinib retains activity in both hematological and certain solid tumor cell lines, as shown by cell viability and cytotoxicity assays (see Data-Driven Solutions).

This article extends mechanistic benchmarks on Dasatinib Monohydrate found in 'Mechanistic and Benchmark Data' by integrating new findings on stromal modulation and assembloid models, as described in Shapira-Netanelov et al., 2025. For advanced applications in assembloid cancer research, see 'Dasatinib Monohydrate in Translational Oncology', which we update here with specific workflow parameters and pitfalls for high-throughput studies.

Applications, Limits & Misconceptions

Dasatinib Monohydrate is routinely used for:

• In vitro kinase inhibition assays targeting ABL, SRC, KIT, and PDGFR pathways.
• Cell viability, proliferation, and cytotoxicity workflows in hematological and solid tumor cell models.
• Preclinical mouse models of CML and Ph+ ALL, including imatinib-resistant disease.
• Personalized drug screening in assembloid and organoid systems integrating tumor and stromal cells (Shapira-Netanelov et al., 2025).
• Mechanistic studies of tyrosine kinase signaling and drug resistance.

Common Pitfalls or Misconceptions

• Dasatinib Monohydrate is not effective against BCR-ABL T315I mutation; alternative inhibitors are required (FDA label).
• It is insoluble in ethanol and water; only DMSO (≥25.3 mg/mL) is recommended for stock preparation (APExBIO).
• Long-term storage of DMSO solutions leads to degradation; use freshly prepared solutions and store solid at -20°C.
• Not all solid tumors respond equally; stromal composition and resistance mechanisms can limit efficacy in complex tumor microenvironments (Shapira-Netanelov et al., 2025).
• Dasatinib is not specific to a single kinase; off-target effects may complicate interpretation in non-ABL/SRC-driven models.

Workflow Integration & Parameters

For optimal results, dissolve Dasatinib Monohydrate at ≥25.3 mg/mL in DMSO and store aliquots at -20°C. Use freshly prepared solutions for each experiment to maintain potency. In standard kinase inhibition assays, apply concentrations ranging from 0.1–100 nM, depending on the assay sensitivity. For cell-based assays, titrate to desired effect, commonly 1–100 nM for BCR-ABL or SRC-driven cell lines. In murine models, oral administration protocols should follow published pharmacokinetic and toxicity parameters (Shapira-Netanelov et al., 2025). For assembloid and organoid applications, incorporate matched stromal subpopulations to mimic clinical tumor heterogeneity and resistance. Consult the Dasatinib Monohydrate product page (SKU B5954, APExBIO) for detailed chemical, solubility, and storage specifications.

Conclusion & Outlook

Dasatinib Monohydrate (BMS-354825) is a gold-standard multitargeted kinase inhibitor with established efficacy in hematological and solid tumor research. Its nanomolar potency, broad kinase spectrum, and ability to overcome imatinib resistance make it indispensable for preclinical studies, particularly in next-generation assembloid models. The integration of patient-specific stromal components, as shown in recent gastric cancer assembloid research, highlights new directions for personalized drug screening and resistance mechanism discovery. For robust, reproducible results, follow recommended solubility and storage protocols. APExBIO provides validated Dasatinib Monohydrate for translational oncology workflows. For further mechanistic insights and protocol guidance, reference complementary articles such as 'Data-Driven Solutions' and 'Translational Oncology', which this article updates with the latest assembloid findings and workflow best practices.